Dr. Jan Belohlavek and Dr. C. Michael Gibson Discuss: Hyperinvasive Approach In Refractory Out-of-hospital Cardiac Arrest: An Open-label Randomized Controlled Trial. Prague OHCA Study May 15, 2021 Disclosures: TBD
Dr. Gregory Marcus and Dr. C. Michael Gibson Discuss: Acute Alcohol Consumption And Discrete Atrial Fibrillation Events May 15, 2021 Disclosures: TBD
Dr. Gregg Stone and Dr. C. Michael Gibson Discuss: Impact Of Completeness Of Revascularization On Clinical Outcomes In Patients With Stable Ischemic Heart Disease Treated With An Invasive Vs. Conservative Strategy: The ISCHEMIA Trial May 15, 2021 Disclosures: TBD
Dr. Behnood Bikdeli and Dr. C. Michael Gibson Discuss: Atorvastatin Versus Placebo In Critically-ill Patients With Covid-19: The Inspiration-S Double Blind Randomized Controlled Trial May 15, 2021 Disclosures: TBD
Dr. Mikhail Kosiborod and Dr. C. Michael Gibson Discuss: Effects Of Dapagliflozin On Prevention Of Major Clinical Events And Recovery In Patients With Respiratory Failure Due To COVID-19 – Main Results From The DARE-19 Randomized Trial May 15, 2021 Disclosures: TBD
Dr. John Teerlink and Dr. C. Michael Gibson Discuss: Impact Of Ejection Fraction On The Therapeutic Effect Of Omecamtiv Mecarbil In Patients With Heart Failure And Reduced Ejection Fraction: A Secondary Analysis From GALACTIC-HF May 15, 2021 Disclosures: TBD
Dr. Douglas Mann and Dr. C. Michael Gibson Discuss: Sacubitril/Valsartan (LCZ696) In Patients With Advanced Heart Failure And Reduced Ejection Fraction: Results Of The LIFE Trial May 15, 2021 Disclosures: TBD
Dr. Rupert Bauersachs and Dr. C. Michael Gibson Discuss: Reductions In Total Ischemic Events With Rivaroxaban In Patients With Symptomatic Pad After Revascularization: The VOYAGER PAD Trial May 15, 2021 Disclosures: TBD
Dr. Pierre Amarenco Presents: Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Tia of Atherosclerotic Origin February 10, 2021 Disclosures: TBA
Dr. Alexandra J Lansky Presents: A Prospective Multicenter Randomized Controlled Trial Assessing the Safety and Efficacy of the BuMA Supreme™ Biodegradable Drug Coated Coronary Stent System in Patients With Stable or Non-ST Elevation Acute Coronary Syndromes: Primary Endpoint Results of the PIONEER III Trial February 10, 2021 Disclosures: TBA
